Chief executive officer, Rapport Therapeutics
Appears in 1 story
Last updated Oct 26, 2026
Leading RAP-219 into Phase 3 planning after a 3.1-point Phase 2 win that fell short of the four-point bar he had set
Rapport Therapeutics' epilepsy pill beat placebo in a mid-stage bipolar mania trial, the company said Oct. 20. The 3.1-point gap on a 60-point mania scale was statistically significant, but it missed the four points chief executive Abraham Ceesay had called clinically meaningful.
Updated Oct 26
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
